Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenuto archiviato il 2024-05-24

Profiling metalloprotease inhibition for tumour therapy

Obiettivo

Inhibitors of metalloproteinases have shown a high therapeutic potency in preliminary clinical trials. However, unacceptable side-effects are associated, which are relative to recently discovered ADAMS and "non classical" effects of MMPs. This project aims at defining the best MMP inhibition profiles for cancer therapy by
1) a comprehensive assessment of metalloprateinase activities and functions at both physiological and tumour progression level, i.e. by using first inhibition inhibitors as probe;
2) designing new metalloproteinase inhibitors on the basis of inhibitor-enzyme complex 3-D structures and on the biological activities to be tackled;
3) assessing the benefit of combining MMP inhibitors with serine proteases inhibitors designed on a similar basis.

Invito a presentare proposte

Data not available

Meccanismo di finanziamento

CSC - Cost-sharing contracts

Coordinatore

UNIVERSITE DE LIEGE*ULG
Contributo UE
Nessun dato
Indirizzo
PLACE DU 20 AOUT 7
4000 LIEGE
Belgio

Mostra sulla mappa

Costo totale
Nessun dato

Partecipanti (9)